mk-4830

MK-4830 is a fully human monoclonal antibody that targets the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4, also known as LILRB2), which is primarily expressed on myeloid cells such as monocytes, macrophages, dendritic cells, and granulocytes. By binding to ILT4, MK-4830 blocks its interaction with ligands and prevents ILT4-mediated signaling. This action abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment, reprograms tumor-associated macrophages to relieve myelosuppression, enhances T cell activity and cytotoxic T lymphocyte-mediated anti-tumor responses, and stimulates pro-inflammatory cytokine production. The drug is being developed for use in various advanced solid tumors both as monotherapy and in combination with pembrolizumab (KEYTRUDA). It has reached Phase II clinical trials for ovarian cancer and has been studied or discontinued in several other cancers including head and neck cancer, soft tissue sarcoma, colorectal cancer, malignant melanoma, non-small cell lung cancer (NSCLC), esophageal cancer, renal cell carcinoma (RCC), small cell lung cancer (SCLC), solid tumors generally; it is also under investigation for pancreatic adenocarcinoma, glioblastoma multiforme (GBM), gastric/gastroesophageal junction adenocarcinoma, triple-negative breast cancer (TNBC), mesothelioma.

Other names

anti-ILT4 monoclonal antibody MK-4830anti-ILT-4 monoclonal antibody MK-4830anti-ILT 4 monoclonal antibody MK-4830anti-immunoglobulin-like transcript 4 monoclonal antibody